Cellectis (CLLS) Share-based Compensation Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 206.26% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -69.95% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 0.18% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.66% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.70% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | 70.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.39% |
| Dec 31, 2025 | -99.90% |
| Sep 30, 2025 | -183.04% |
| Jun 30, 2025 | 99.61% |
| Mar 31, 2025 | 10.03% |
| Dec 31, 2024 | 49,373.43% |
| Sep 30, 2024 | -121.33% |
| Jun 30, 2024 | 49.57% |
| Mar 31, 2024 | -45.25% |
| Dec 31, 2023 | 1,094.06% |
| Sep 30, 2023 | 26,475.18% |
| Jun 30, 2023 | -24,677.96% |
| Mar 31, 2023 | -30.05% |
| Dec 31, 2022 | -79.98% |
| Sep 30, 2022 | 80.20% |
| Jun 30, 2022 | -266.49% |
| Mar 31, 2022 | 7,620.00% |
| Dec 31, 2021 | 169.53% |
| Sep 30, 2021 | 63.86% |
| Jun 30, 2021 | -14.21% |
| Mar 31, 2021 | -99.37% |
| Dec 31, 2020 | -139.19% |
| Sep 30, 2020 | -57.62% |
| Jun 30, 2020 | -30.77% |
| Mar 31, 2020 | -6.21% |
| Dec 31, 2019 | -11.93% |
| Sep 30, 2019 | -2.01% |
| Jun 30, 2019 | -25.40% |
| Mar 31, 2019 | -57.63% |
| Dec 31, 2018 | -29.83% |
| Sep 30, 2018 | -36.78% |
| Jun 30, 2018 | -67.92% |
| Mar 31, 2018 | -11.74% |
| Dec 31, 2017 | -18.53% |
| Sep 30, 2017 | -4.77% |
| Jun 30, 2017 | 72.72% |
| Mar 31, 2017 | -7.97% |
| Dec 31, 2016 | 1.83% |
| Sep 30, 2016 | 28.46% |
| Jun 30, 2016 | 104.87% |
| Mar 31, 2016 | 1,459.00% |